Clinical Trial Update: Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

Clinical trial update indicates a phase 2 study of Calquence (acalabrutinib) for ibrutinib-intolerant mantle cell lymphoma is active but not currently recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• CALQUENCE (ACALABRUTINIB)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Mantle Cell Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING